Efficacy of a three drug-based therapy for neuroblastoma in mice

Patrizia Garbati, Raffaella Barbieri, Matilde Calderoni, Francesca Baldini, Mario Nizzari, Paola Modesto, Tullio Florio, Aldo Pagano

Research output: Contribution to journalArticlepeer-review


High-risk neuroblastoma (HR-NB) still remains the most dangerous tumor in early child-hood. For this reason, the identification of new therapeutic approaches is of fundamental importance. Recently, we combined the conventional pharmacological approach to NB, represented by cisplatin, with fendiline hydrochloride, an inhibitor of several transporters involved in multidrug resistance of cancer cells, which demonstrated an enhancement of the ability of cisplatin to induce apoptosis. In this work, we co-administrated acetazolamide, a carbonic anhydrase isoform IX (CAIX) inhibitor which was reported to increase chemotherapy efficacy in various cancer types, to the cisplatin/fendiline approach in SKNBE2 xenografts in NOD-SCID mice with the aim of identifying a novel and more effective treatment. We observed that the combination of the three drugs increases more than twelvefold the differences in the cytotoxic activity of cisplatin alone, leading to a remarkable decrease of the expression of malignancy markers. Our conclusion is that this approach, based on three FDA-approved drugs, may constitute an appropriate improvement of the pharmacological approach to HR-NB.

Original languageEnglish
Article number6753
JournalInternational Journal of Molecular Sciences
Issue number13
Publication statusPublished - Jul 1 2021


  • Acetazolamide
  • CAIX
  • Drug repositioning
  • Fendiline hydrochloride
  • Neuroblastoma
  • Non-coding RNAs

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Efficacy of a three drug-based therapy for neuroblastoma in mice'. Together they form a unique fingerprint.

Cite this